Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.

TD Cowen kept a Hold rating on UPS with a $116 price target, suggesting a 9.3% upside from the Oct 27 close. UPS beat Q3 earnings expectations with an adjusted EPS of $1.69, and forecasts volume growth through 2027, focusing on B2B markets.

The UK's HMRC awarded Salesforce a £2.4bn contract to modernize its customer services, replacing outdated systems with a single CRM platform. The deal aims to improve service efficiency and expand AI-assisted taxpayer services, with the contract running until 2036, extendable to 2041. Salesforce will provide AI capabilities and a unified view of taxpayer interactions.

Scotiabank kept its Sector Outperform rating on Freeport-McMoRan (FCX) with a $78 price target, suggesting 18.3% upside. The bank expects improved free cash flow and strong leverage to copper and gold prices.

Volkswagen (VWAGY) is shifting its China strategy to focus on exports due to weak domestic demand and competition. The company expects China's auto market to shrink from 24M to 19M vehicles in 2026, with VW aiming to maintain an 11% market share. VW plans to use Chinese joint ventures to expand into Southeast Asia, Africa, and South America, leveraging locally developed technology for global exports.

TD Cowen kept a Buy rating on HCA Healthcare with a $486 price target, suggesting 8% upside from the last close. The firm cites strong growth prospects, effective cost management, and a robust balance sheet for its optimism.